Quote | Lumos Pharma Inc. (NASDAQ:LUMO)
Last: | $2.77 |
---|---|
Change Percent: | 0.59% |
Open: | $2.7436 |
Close: | $2.77 |
High: | $2.78 |
Low: | $2.7436 |
Volume: | 688 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
News | Lumos Pharma Inc. (NASDAQ:LUMO)
AUSTIN, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that abstracts reviewing data from its Phase ...
Lumos Pharma (NASDAQ: LUMO) , a biopharmaceutical company advancing an oral therapeutic candidate for pediatric growth hormone deficiency (“PGHD”) through phase 2 clinical trials, has received a notice of allowance for a submitted patent. The notice was received from the U.S. P...
Message Board Posts | Lumos Pharma Inc. (NASDAQ:LUMO)
Subject | By | Source | When |
---|---|---|---|
I recently bought shares based mainly on the | fishhunter | investorshub | 09/19/2021 8:53:02 PM |
whytestocks: $NLNK News Article - NewLink Genetics Announces FDA Approval of Ebola Vaccine V920 (ERV | whytestocks | investorshangout | 12/20/2019 3:30:42 PM |
whytestocks: $NLNK News Article - NewLink Genetics Announces EU Regulatory Committee (CHMP) Recommen | whytestocks | investorshangout | 10/21/2019 8:35:44 PM |
whytestocks: $NLNK News Article - Captivating Stock- NewLink Genetics Corporation (NASDAQ:NLNK) | whytestocks | investorshangout | 08/21/2019 8:45:40 PM |
whytestocks: $NLNK News Article - NewLink Genetics Provides Corporate Update and Reports Second Quar | whytestocks | investorshangout | 07/30/2019 7:25:40 PM |
News, Short Squeeze, Breakout and More Instantly...
Lumos Pharma Inc. Company Name:
LUMO Stock Symbol:
NASDAQ Market:
AUSTIN, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that abstracts reviewing data from its Phase ...
Lumos Pharma (NASDAQ: LUMO) , a biopharmaceutical company advancing an oral therapeutic candidate for pediatric growth hormone deficiency (“PGHD”) through phase 2 clinical trials, has received a notice of allowance for a submitted patent. The notice was received from the U.S. P...
AUSTIN, Texas, March 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic ca...